Navigation Links
AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Date:10/1/2008

H

The first multi-center efficacy study for which patient recruitment was completed in April 2008, is currently being conducted primarily in the United States and Canada, with additional sites in Europe and involves approximately 600 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NY University School of Medicine, New York. Patients enter a 4-week run-in no-treatment observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients receive cetrorelix by IM injection at Week 52, 54, 78 and 80 and are followed up to Week 90.

The second multi-center Phase 3 efficacy study for which patient recruitment completion was announced today, involves approximately 400 patients, mainly in Europe. Patients in this randomized placebo-controlled study with open-label extension, receive cetrorelix according to similar dosing regimens used in the first study.

The primary endpoint for both North American and European efficacy studies is absolute change in IPSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH symptom progression and the need for BPH-related surgery. Safety endpoints include changes in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The third study in the Phase 3 program, a multi-center safety study, for which patient recruitment started in May 2008, is an ongoing open-label, single-armed study involving approximately 500 patients in both North America and Europe.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
2. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
3. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
4. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
5. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
6. AEterna Zentaris Sells Quebec City Building for $7.1 million
7. AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global Healthcare Conference and AUA Annual Meeting
8. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
9. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
10. AEterna Zentaris to Announce First Quarter 2008 Financial and Operating Results and Hold Annual Shareholder Meeting on May 7, 2008
11. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... (PRWEB) April 01, 2015 ... (AFM) was selected to receive the prestigious “Best ... Economy Magazine.    Park NX10 is the premium research-grade True ... Z scanner linearity, closed-loop detector noise, and minimized ... SmartSca n, which allows images with a ...
(Date:4/1/2015)... 1, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... pleased to announce that Biohaven Pharmaceutical Holding Company ... entered into an agreement with inVentiv Health for ... with their lead compound (BHV-0223). ... of clinical stage neuroscience compounds targeting the glutamatergic ...
(Date:4/1/2015)... April 1, 2015  Among 1,050 U.S. consumers, the ... cancer (68 percent) and only 36 percent reported being ... according to findings from a survey released ... innovator and developer of solutions that aid in the ... online survey polled 1,050 U.S. consumers on their knowledge ...
(Date:4/1/2015)... and NEW YORK , April ...  PTBI), a biopharmaceutical company advancing protein biologic therapies ... overview of the Company,s 2014 achievements and a ... demonstrate the progress the Company has made in ... partnerships for its MuGard programs, the FDA clearance ...
Breaking Biology Technology:Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6
... AMSTERDAM, November 11 Amsterdam Molecular,Therapeutics (Euronext: AMT), ... today that it has successfully treated Duchenne muscular dystrophy,(DMD) ... The proof of,concept studies were performed in collaboration with ... Sapienza, Italy) and demonstrated,effectiveness in the heart as well ...
... THE WOODLANDS, Texas, Nov. 10 Today, US ... , executive vice president and general counsel, will be ... http://www.newscom.com/cgi-bin/prnh/20091110/DA08765 ) , Watts has had a long ... worked with US Oncology providing legal services and consultation as ...
... , ST. LOUIS, Nov. 10 At the Board of ... dividend of $.145 per share, an 11.5% increase over the ... 2009 to shareholders of record on December 1, 2009. , ... Life Science and High Technology company. Our chemical and biochemical ...
Cached Biology Technology:AMT Successful in Preclinical Treatment of DMD 2AMT Successful in Preclinical Treatment of DMD 3US Oncology Announces Retirement of General Counsel Phil Watts 2
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... research published today in BioMed Central,s open access journal ... Rafflesia cantleyi , with its 50cm diameter flowers, has ,stolen, ... these genes shows that their functions range from respiration to ... parasites own gene activity. Vertical gene transfer is that ...
... of North America, are in trouble mostly because of inadequate ... impact, according to work published June 6 in the open ... led by Katherine Ayres, who completed the work while at ... fecal thyroid and glucocorticoid, to distinguish between two different theories ...
... Communities of microbial organisms -- species such as ... Gulf of Mexico changed significantly following the Deepwater Horizon ... of New Hampshire,s Hubbard Center for Genome Studies (HCGS) ... from five Gulf Coast sites prior to and several ...
Cached Biology News:Parasitic plants 'steal' genes from their hosts 2Microbial communities shifted dramatically after Deepwater Horizon spill 2
... Protein Purification Protocols covers a wide ... for novice and experienced researchers in all ... This excerpt from the books preface illustrates ... to your research library., The chapters introduce ...
... is an easy-to-use siRNA transfection reagent that ... genes in a variety of cell lines. ... an optimized, straightforward protocol. High levels of ... following transfection of 20 to 100 nM ...
... The lower cost and reduced ... system make reference standard DNA analysis ... be used with any of SEQUENOM's ... High-Performance Genotyping (iPLEXTM Gold) , Gene ...
... all the features of Tracker, plus software that ... a user defined period of time in a ... family of instruments all built around a video ... that can track two fields at once and ...
Biology Products: